A Phase III randomised, Open-Label, Multi-centre study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination with Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma not Eligible for Transplant (IMROZ)
- Low, Michael (Primary Chief Investigator (PCI))
Project: Research